Autoimmune disease

Handshake
#Autoimmune disease #Collaboration #Drug development #Drug targets #Funding #Partnership

Agreement to develop drug target for multiple autoimmune diseases 

Affibody partnered with ACELYRIN to develop and commercialise izokibep, a bispecific molecule targeting interleukin-17A (IL-17), for multiple autoimmune diseases.   Izokibep is an antibody mimetic, IL-17A inhibitor designed to overcome the limitations of monoclonal antibodies. With extraordinary potency and small molecular size, izokibep can reach high drug exposure levels through a single subcutaneous… Read More

#News

#Autoimmune disease #Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Moderna #Pfizer

NIH studies Covid-19 vaccine dose for people with autoimmune disease 

The National Institutes of Health (NIH) has begun a clinical trial to assess the antibody response to an extra dose of an authorised or approved Covid-19 vaccine in people with autoimmune disease who did not respond to an original Covid-19 vaccine regimen.   The trial will also investigate whether pausing… Read More

#Covid-19 #News #Trending News

#Autoimmune disease #Research #Study

Study explains why autoimmune diseases affect women more than men

A study led by an international team of researchers has made an important breakthrough in terms of understanding the causes of primary biliary cholangitis (PBC). The programme was coordinated by experts from the University of Milano-Bicocca and the Autoimmune Diseases of the Liver Centre at the San Gerardo Hospital in Monza,… Read More

#News

#Autoimmune disease #Drug candidates #Drug discovery

Beetroot peptide potential drug candidate for neurodegenerative and inflammatory diseases

In a recent study, a research group led by Christian Gruber at MedUni Vienna’s Institute of Pharmacology isolated a peptide (small protein molecule) from beetroot. The peptide is able to inhibit a particular enzyme that is responsible for the breakdown of messenger molecules in the body. Due to its particularly… Read More

#Editor's Choice #News

#Autoimmune disease #Cancer

Tapping a staggering market potential

Dr Michael Shepard and Sir Marc Feldmann, Enosi Life Sciences, examine the benefits of distinguishing between TNF receptors. Siloed thought processes are potentially costing the pharmaceutical industry billions of dollars per year. One particularly interesting case is that of autoimmune diseases and cancer. These two areas of medicine have a… Read More

#Exclusive Content